Cagrilintide is a long-acting amylin-analog peptide under investigation for weight management research through appetite suppression, satiety extension, and glucose regulation. Recent clinical trials demonstrate significant dose-dependent weight reduction and metabolic improvements, with potential for combination approaches alongside GLP-1 receptor agonists.
More
Updating…